Aprecia is a specialty pharmaceutical company using its proprietary 3D printing technology to develop and manufacture pharmaceuticals. The company’s ZipDose formulation platform enables rapid dissolving forms of drugs that are beyond the formulation limits of existing fast-melt technologies. The company obtained FDA approval in 2015 for its lead product Spritam, an oral fast-melt form of levetiracetam (Keppra) for epilepsy, and is developing novel formulations of several other epilepsy drugs.